Physician profile
Ryan P Buffalo
NPI 1356330666
$4,317.19
in general payments reported to CMS, 2019-2025
31 companies · $840 in 2025
The $840 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $511 · 2020: $230 · 2021: $24.45 · 2022: $563 · 2023: $1,166 · 2024: $982 · 2025: $840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,988.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,988.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $719.03 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $475.08 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $425.57 | 2019-2025 | |
| Abbvie INC. | $310.72 | 2022-2025 | Vraylar, Ubrelvy |
| Otsuka America Pharmaceutical, INC. | $308.53 | 2022-2024 | Rexulti, Abilify Maintena |
| Amgen INC. | $292.81 | 2019-2024 | Evenity, Prolia, Repatha |
| Astellas Pharma US INC | $244.41 | 2019-2023 | Myrbetriq |
| Almatica Pharma LLC | $150.37 | 2024-2025 | Loreev Xr |
| Sumitomo Pharma America, INC. | $141.82 | 2023-2024 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.70 | 2019-2025 | Jardiance |
| Abbott Laboratories | $129.45 | 2021-2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $118.36 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $84.35 | 2020-2025 | Capvaxive, Gardasil 9 |
| Novo Nordisk INC | $83.41 | 2019-2024 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.55 | 2024-2025 | Xifaxan |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $75.47 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $73.80 | 2022 | |
| Lucid Diagnostics INC. | $63.05 | 2022 | |
| Lundbeck LLC | $58.24 | 2022-2024 | Rexulti |
| Genentech USA, INC. | $51.36 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $43.56 | 2022-2023 | Eliquis |
| Janssen Pharmaceuticals, INC | $39.89 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.08 | 2023-2024 | |
| Verona Pharma, INC. | $32.34 | 2025 | Ohtuvayre |
| Sunovion Pharmaceuticals INC. | $31.67 | 2022 | |
| Exact Sciences Corporation | $29.36 | 2023-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $26.05 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $22.39 | 2023 | Austedo Xr |
| Kowa Pharmaceuticals America, INC. | $15.51 | 2025 | Zoryve |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.74 | 2025 | Caplyta |
| Allergan, INC. | $11.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Buffalo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.